文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌患者的三联疗法与根治性膀胱切除术:比较性研究的系统综述与Meta分析

Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
PubMed 文献 · BJU Int · 2024-04-15

该系统综述与Meta分析比较了三联疗法(TMT)与根治性膀胱切除术(RC)在肌层浸润性膀胱癌患者中的肿瘤学结局、生活质量和费用。结果显示两组总生存(HR 1.07,95%CI 0.81-1.4;P=0.6)、癌症特异性生存(HR 1.12,95%CI 0.79-1.57;P=0.5)和无转移生存(HR 0.88,95%CI 0.66-1.16;P=0.3)均无显著差异;TMT平均费用显著更高(289142美元 vs 148757美元;P<0.001),但每质量调整生命年成本效果更优,且总体生活质量评分显著更高。

要点

  • TMT与RC在OS、CSS和MFS上均无显著差异。
  • TMT平均费用显著高于RC,但每质量调整生命年成本效果更优。
  • TMT的总体生活质量评分显著更高。

核心结论

  • 三联疗法在OS、CSS和MFS方面似乎与根治性膀胱切除术相当,同时提供更优的患者生活质量和成本效果。

研究设计与样本

  • 系统综述与Meta分析,于2023年7月检索多个数据库,纳入比较cT2-4 N any M0肌层浸润性膀胱癌患者接受TMT与RC的对照研究。

主要发现

  • RC与TMT的总生存无显著差异(HR 1.07,95%CI 0.81-1.4;P=0.6)。
  • 放射治疗方案≥60 Gy时总生存仍无显著差异(HR 1.02,95%CI 0.69-1.52;P=0.9)。
  • 癌症特异性生存无显著差异(HR 1.12,95%CI 0.79-1.57;P=0.5)。
  • 无转移生存无显著差异(HR 0.88,95%CI 0.66-1.16;P=0.3)。
  • TMT平均费用显著高于RC(289142美元 vs 148757美元;P<0.001),但每质量调整生命年成本效果更优,且总体生活质量评分显著更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a systematic review and meta-analysis of trials comparing trimodal therapy (TMT) and radical cystectomy (RC), evaluating differences in terms of oncological outcomes, quality of life, and costs. MATERIALS AND METHODS: In July 2023, a literature search of multiple databases was conducted to identify studies analysing patients with cT2-4 N any M0 muscle-invasive bladder cancer (MIBC; Patients) receiving TMT (Intervention) compared to RC (Comparison), to evaluate survival outcomes, recurrence rates, costs, and quality of life (Outcomes). The primary outcome was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS) and metastasis-free survival (MFS). Hazard ratios (HRs) were used to analyse survival outcomes according to different treatment modalities and odds ratios were used to evaluate the likelihood of receiving each type of treatment according to T stage. RESULTS: No significant difference in terms of OS was observed between RC and TMT (HR 1.07, 95% confidence interval [CI] 0.81-1.4; P = 0.6), even when analysing radiation therapy regimens ≥60 Gy (HR 1.02, 95% CI 0.69-1.52; P = 0.9). No significant difference was observed in CSS (HR 1.12, 95% CI 0.79-1.57, P = 0.5) or MFS (HR 0.88, 95% CI 0.66-1.16; P = 0.3). The mean cost of TMT was significantly higher than that of RC ($289 142 vs $148 757; P < 0.001), with greater effectiveness in terms of cost per quality-adjusted life-year. TMT ensured significantly higher general quality-of-life scores. CONCLUSION: Trimodal therapy appeared to yield comparable oncological outcomes to RC concerning OS, CSS and MFS, while providing superior patient quality of life and cost effectiveness.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ditonno F, Veccia A, Montanaro F, et al. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. 2024. PMID: 38622957. doi:10.1111/bju.16366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。